Abstract:Abstract Recent next-generation sequencing experiments have brought success in identifying cancer genes that were highly frequently mutated in tumors. As genomic sequencing experiments continue to identify large numbers of novel cancer mutations, one big challenge will be distinguishing driver mutations from passenger mutations. Driver mutations are the ones that have a role in oncogenesis or in the cancer phenotype, whereas passenger mutations are co-traveler that accumulate through DNA replication but are irrelevant to tumor development. From statistical point of view, driver genes are defined as those for which the non-silent mutation rate is significantly greater than a background (or passenger) mutation rate estimated from silent mutations. Statistical methods are now actively being developed to attempt to assess functional significance of a mutated gene in cancer sequencing studies. However, embedding biological knowledge on mutational process in tumors into statistical models is not trivial. These biological considerations include length of protein coding regions, gene structure, transcript isoforms, difference in mutation types, variation in background mutation rates, redundancy of the genetic code, multiple mutations in one gene, and functional consequence of different tumor types. They have not yet been fully addressed by current methods and tools for identifying driver genes. Driver mutations could be either common or rare among tumors. Identification of rare driver mutations may pose a potential challenge. In addition, mutation in one member of a collection of functionally related genes may result in the same net effect, and/or mutations in certain genes may be observed less frequently if they play functional roles in later stages of tumor development. At the pathway level, the frequency of rare driver mutations is accumulated in that pathway which warrants sufficient detection power. Thus, there is an increasing interest in the identification of driver pathways in tumor formation and progression. To meet these challenges, we developed a tool-DrGaP for identify driver genes and pathways in cancer sequencing studies. We introduced the Poisson processes to model the random nature of somatic mutation under no selection pressure. The new model can handle the identification of both driver genes and pathways or any gene sets in the same statistical framework. The new tool provides several significant improvements and increased power over current existing methods through simulations. To illustrate its utility, we applied the DrGaP to analysis of a recent lung cancer sequencing study. The DrGaP identified a few novel driver genes that were missed by previous methods, demonstrating its high accuracy and sensitivity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3971. doi:1538-7445.AM2012-3971

The Human Kinase‐substrate Phosphorylation Network Rewired by Genetic Polymorphisms is Heavily Associated with Cancers (984.3)

Reconfiguring phosphorylation signaling by genetic polymorphisms affects cancer susceptibility.

PhosSNP for Systematic Analysis of Genetic Polymorphisms That Influence Protein Phosphorylation*

Construction and Analysis of Human Phosphorylation Network

Abstract 3971: DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies

Multiple Gene Dysfunctions Lead to High Cancer-Susceptibility: Evidences from a Whole-Exome Sequencing Study.

Spatially Interacting Phosphorylation Sites and Mutations in Cancer

In silico approaches uncovering the systematic function of N-phosphorylated proteins in human cells.

Phosphoproteomics of extracellular vesicles integrated with multiomics analysis reveals novel kinase networks for lung cancer

Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by information theory

Systematic Analysis of Protein Phosphorylation Networks From Phosphoproteomic Data

Phosphoproteomics‐based Network Medicine

AWESOME: a Database of SNPs That Affect Protein Post-Translational Modifications.

PhosCancer: A Comprehensive Database for Investigating Protein Phosphorylation in Human Cancer

Characterization of DNA Variants in the Human Kinome in Breast Cancer

Identification of Phosphorylation Associated SNPs for Blood Pressure, Coronary Artery Disease and Stroke from Genome-wide Association Studies

Identifying Protein Phosphorylation Site-Disease Associations Based on Multi-Similarity Fusion and Negative Sample Selection by Convolutional Neural Network

Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring

Quantitative phosphoproteomics-based molecular network description for high-resolution kinase-substrate interactome analysis